UBS analyst Colin Bristow downgraded shares of Merck to Neutral (NYSE: MRK) on the lack of evident catalysts and the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE